 |
市場調查報告書
商品編碼
1524241
布洛芬API 市場- 按類型（標準布洛芬、高效布洛芬）、應用（頭痛、關節炎、發燒、牙痛）、最終用途（製藥和生物製藥公司、CDMO）、全球預測（2024 - 2032 ）Ibuprofen API Market - By Type (Standard Ibuprofen, High Potency Ibuprofen), Application (Headache, Arthritis, Fever, Dental Pain), End-use (Pharmaceutical & Biopharmaceutical Companies, CDMOs), Global Forecast (2024 - 2032) |
||||||
由於布洛芬廣泛應用於用於緩解疼痛和發燒的非處方非處方藥中，2024 年至 2032 年間，全球布洛芬 API 市場的複合年成長率將超過 3.7%。隨著越來越多的消費者尋求常見疾病的可行解決方案，非處方藥中對布洛芬的需求持續成長。這種趨勢得到了人們對自我藥療的偏好以及無需處方即可購買此類藥物的便利性的支持。
據工業和資訊化部工信部稱，2022年12月，中國布洛芬和對乙醯氨基酚的日產量自12月初以來翻了兩番。這一成長是政府和藥品製造商加大努力的結果，以確保感冒和發燒藥物的充足供應，以滿足不斷成長的市場需求。
製藥公司正在透過配方和輸送系統創新來利用這一需求，提高含布洛芬產品在全球市場的吸引力和有效性。
整個布洛芬 API 市場根據類型、應用、最終用途和地區進行分類。
預測期內，標準布洛芬產業將實現大幅複合年成長率成長。標準布洛芬配方可滿足廣泛的疼痛緩解需求，從日常疼痛到更嚴重的病症。這種多功能性使布洛芬成為全球藥物製劑的主要成分，帶來了持續的需求。此外，其既定的安全性和監管批准增強了其吸引力，確保在醫療保健環境中廣泛採用。隨著製藥公司不斷創新新配方和劑型，對布洛芬 API 的需求持續成長，反映了其在疼痛管理解決方案中不可或缺的角色。
到 2032 年，由於布洛芬在治療頭痛和偏頭痛方面的有效性，頭痛領域將佔據相當大的市場佔有率。隨著越來越多的人尋求可靠地緩解這些常見疾病，含有布洛芬的藥物製劑因其快速作用和效力而越來越受到青睞。布洛芬作為非處方藥的可近性刺激了其在這一領域的需求，使消費者能夠方便地處理偶爾的頭痛。此外，針對緩解頭痛的改進給藥系統和配方的持續研究繼續擴大布洛芬 API 的市場，有效滿足不同患者的需求。
從2024年到2032年，北美布洛芬原料藥市場將錄得令人印象深刻的複合年成長率。中國、印度和日本等國家的經濟發展和醫療保健支出的增加正在擴大藥品（包括止痛藥）的取得範圍。都市化進程的不斷加速和生活方式的改變導致需要疼痛管理的疾病發生率更高，從而推動了布洛芬原料藥產業的發展。此外，促進醫療保健基礎設施發展和改善醫療保健可近性的政府措施刺激了布洛芬原料藥的需求。歐洲不斷發展的監管環境透過促進藥品製造商更容易進入市場和合規性來支持市場擴張。
目錄
第 1 章：方法與範圍
第 2 章：執行摘要
第 3 章：產業洞察
- 產業生態系統分析
- 產業影響力
- 成長動力
- 疼痛狀況的盛行率不斷增加
- 對非處方藥 (OTC) 的需求不斷成長
- 老年人口不斷增加
- 產業陷阱與挑戰
- 對布洛芬副作用的擔憂
- 替代產品的可用性
- 成長動力
- 成長潛力分析
- 監管環境
- 波特的分析
- PESTEL分析
第 4 章：競爭格局
- 介紹
- 公司矩陣分析
- 主要市場參與者的競爭分析
- 競爭定位矩陣
- 戰略儀表板
第 5 章：市場估計與預測：按類型，2021 - 2032
- 主要趨勢
- 標準布洛芬
- 高效布洛芬
第 6 章：市場估計與預測：按應用分類，2021 - 2032
- 主要趨勢
- 頭痛
- 關節炎
- 發燒
- 牙齒疼痛
- 其他應用
第 7 章：市場估計與預測：按最終用途，2021 - 2032 年
- 主要趨勢
- 製藥及生物製藥公司
- CDMO 的
第 8 章：市場估計與預測：按地區，2021 - 2032
- 主要趨勢
- 北美洲
- 美國
- 加拿大
- 歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
- 亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
- 拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
- 中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區
第 9 章：公司簡介
- BASF Corporation
- Dr. Reddy's Laboratories Ltd
- Granules India Limited
- IOL Chemicals and Pharmaceuticals Limited
- Octavius Pharma Pvt. Ltd
- SI Group, Inc.
- Solara Active Pharma Sciences Limited
- Strides Pharma Science Limited
- Rochem International Inc.
- Teva Pharmaceutical Industries Ltd.
Global Ibuprofen API Market will register over 3.7% CAGR between 2024 and 2032, owing to its widespread inclusion in over-the-counter OTC medications used for pain and fever relief. As more consumers seek accessible solutions for common ailments, the demand for Ibuprofen in OTC products continues to grow. This trend is supported by a preference for self-medication and the convenience of purchasing such medications without prescriptions.
Quoting an instance, in December 2022, China daily production of ibuprofen and acetaminophen quadrupled since early December, according to the Ministry of Industry and Information Technology MIIT. This increase is a result of intensified efforts by the government and drug manufacturers to ensure an adequate supply of cold and fever-reducing medications in response to surging market demand.
Pharmaceutical companies are capitalizing on this demand by innovating in formulations and delivery systems, improving the appeal and effectiveness of Ibuprofen-containing products in the global market.
The overall Ibuprofen API market is classified based on type, application, end-use, and region.
During the forecast period, the standard ibuprofen sector will achieve substantial CAGR growth. Standard Ibuprofen formulations cater to a broad spectrum of pain relief needs, ranging from everyday aches to more acute conditions. This versatility makes Ibuprofen a staple in pharmaceutical formulations globally, ushering in consistent demand. Additionally, its established safety profile and regulatory approvals bolster its appeal, ensuring widespread adoption across healthcare settings. As pharmaceutical companies innovate with new formulations and dosage forms, the demand for Ibuprofen API continues to grow, reflecting its integral role in pain management solutions.
By 2032, the headache sector will hold a considerable ibuprofen API market share because of its effectiveness in managing headaches and migraines. As more individuals seek reliable relief from these common ailments, pharmaceutical formulations containing Ibuprofen are increasingly preferred for their rapid action and potency. The accessibility of Ibuprofen as an OTC medication fuels its demand in this segment, allowing consumers to manage occasional headaches conveniently. Moreover, ongoing research into improved delivery systems and formulations tailored to headache relief continues to expand the market for Ibuprofen API, meeting diverse patient needs effectively.
From 2024 to 2032, the North America ibuprofen API market will record an impressive CAGR. Economic development and increasing healthcare expenditures across countries like China, India, and Japan are expanding access to pharmaceuticals, including pain relief medications. Rising urbanization and changing lifestyles contribute to higher incidences of conditions requiring pain management, boosting the ibuprofen API industry. Moreover, governmental initiatives promoting healthcare infrastructure development and improving healthcare access stimulate ibuprofen API demand. Europe's evolving regulatory environment supports market expansion by facilitating easier market entry and compliance for pharmaceutical manufacturers.
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Market scope & definitions
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360° synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Increasing prevalence of pain conditions
- 3.2.1.2 Rising demand for over the counter (OTC) medications
- 3.2.1.3 Growing geriatric population
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 Concerns about the side effects of Ibuprofen
- 3.2.2.2 Availability of substitute products
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Porter's analysis
- 3.6 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company matrix analysis
- 4.3 Competitive analysis of major market players
- 4.4 Competitive positioning matrix
- 4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Standard ibuprofen
- 5.3 High potency ibuprofen
Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Headache
- 6.3 Arthritis
- 6.4 Fever
- 6.5 Dental pain
- 6.6 Other applications
Chapter 7 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 Pharmaceutical & biopharmaceutical companies
- 7.3 CDMO's
Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)
- 8.1 Key trends
- 8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
- 8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
- 8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Rest of Latin America
- 8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa
Chapter 9 Company Profiles
- 9.1 BASF Corporation
- 9.2 Dr. Reddy's Laboratories Ltd
- 9.3 Granules India Limited
- 9.4 IOL Chemicals and Pharmaceuticals Limited
- 9.5 Octavius Pharma Pvt. Ltd
- 9.6 SI Group, Inc.
- 9.7 Solara Active Pharma Sciences Limited
- 9.8 Strides Pharma Science Limited
- 9.9 Rochem International Inc.
- 9.10 Teva Pharmaceutical Industries Ltd.
